Indications: Laronib (Larotrectinib INN) is prescribed for treating solid tumors that exhibit neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation. It’s applicable to various cancer types, including pediatric patients aged one year and older, adults with NTRK gene fusion solid tumors, and those with metastatic solid tumors who have exhausted other treatment options.

Pharmacology: Laronib (Larotrectinib INN) operates as a tyrosine kinase inhibitor, selectively targeting tropomyosin receptor kinases (TRK) A, B, and C. By inhibiting these receptors, it hampers the growth and spread of cancer cells carrying NTRK gene fusions.

Dosage and Administration: Typically, Laronib (Larotrectinib INN) is prescribed at a dosage of 100 mg taken orally twice daily, with or without food. Adjustments to the dosage might be necessary based on individual patient response and tolerance.

Interactions: Laronib (Larotrectinib INN) may interact with specific medications, particularly strong CYP3A inhibitors and inducers. Patients should inform healthcare providers about all medications to avoid potential interactions.

Side Effects: Common side effects of Laronib (Larotrectinib INN) include fatigue, nausea, dizziness, vomiting, anemia, elevated liver enzyme levels, constipation, diarrhea, and cough. Serious adverse effects may comprise hepatotoxicity, neurotoxicity, and embryo-fetal toxicity.

Precautions and Warnings: Patients undergoing treatment with Laronib (Larotrectinib INN) should be monitored for signs of hepatotoxicity, neurotoxicity, and embryo-fetal toxicity. Adjustments or discontinuation of the medication might be required based on the severity of adverse reactions.

Overdose Effects: In case of overdose, supportive measures are warranted. Although specific effects of Laronib (Larotrectinib INN) overdose are limited in information, management should focus on symptomatic and supportive care